arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

INSMED Inc

INSM
$131.15 ▼ -1.46 (-1.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

INSMED Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $26.1B
Dividend Yield
Revenue Growth 66.7%
Op. Margin -205.6%
ROIC -97.4%
FCF / Share $-4.86
Trailing P/E
Price / Book 38.0x
FCF Yield
Debt / Equity 0.74
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$606.42M
↑ +66.7%
Net Income Profit after all expenses
$-1.28B
↓ -39.7%
Operating Margin Operating profit as % of sales
-205.6%
↑ +14.9% 0th
FCF / Share Free cash flow per share
$-4.86
↓ -13.0%
Long-Term Debt Long-term obligations
$546.77M
↓ -51.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
4
Financial Health
32
Cash Quality
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 65 quarters